The Scottish Medicines Consortium (SMC) recently announcement of their approval of Givinostat for the treatment of Duchenne muscular dystrophy (DMD) for restricted use in ambulatory patients 6 years or older (SMC Article). We know many of you will be eager to hear of any updates regarding the National Institute for Health and Care Excellence (NICE) progress for appraising Givinostat for use via NHS England (with Wales and N. Ireland also being informed by the NICE decision).

The NICE recently shared an update on the current progress for the Givinostat appraisal:

Following the committee meeting on 23rd October, this appraisal has been paused to allow the company and NHS England to enter into a commercial discussion. We will provide further updates when available.

This is currently the full information we have from the NICE, and we will continue to monitor the progress and provide the community with update as soon as they become available.

You can read more from the NICE about the Givinostat appraisal here.